ML signed the awaited deal for its inhaler drug last week. expect the announcement in a week.

M.L. Laboratories PLC
06 April 2005

ML Laboratories PLC

Appointment of Non-Executive Director


St Albans, UK, 6 April 2005 - ML Laboratories PLC (LSE: MLB) today announces the
appointment of Fred Hallsworth as a non-executive director and Chairman of the
Audit Committee with immediate effect.

From 2002 until the end of January 2005, Fred Hallsworth, BAcc, CA, was Senior
Client Service Partner at Deloitte. Prior to this, Fred spent 25 years with
Andersen where he held a number of senior management positions, including
Managing Partner of the Cambridge office, and latterly Managing Partner of
Scotland. His recent life sciences experience includes working with Inveresk
Research Group Inc on the 1999 management buyout, the 2001 acquisition of
Clintrials, the IPO on NASDAQ in 2002, and the $3.5 billion merger with Charles
River Laboratories, Inc in 2004. Fred is a Non-Executive Director of Scottish
Enterprise and has held a number of other Board positions, including at CBI
Scotland, Scottish Institute for Enterprise and the University of Cambridge
Finance Committee.

Ian Kent, Executive Chairman of ML Laboratories, said:

'We are delighted to welcome Fred to the Board and as Chair of the Audit
Committee. With his extensive financial experience, including fundraisings,
mergers and acquisitions and other corporate transactions, Fred will provide a
valuable contribution as we implement our turnaround plans for the Group.'

There are no details to be disclosed under paragraph 6.F.2 (b) to (g) of the
Listing Rules.

Contacts:

ML Laboratories Tel: 01727 739300
Ian Kent, Executive Chairman
Kieran Murphy, Chief Executive Officer

Financial Dynamics Tel: 07747 602 739 / 020 7831 3113
Sarah MacLeod / David Yates

Notes to Editors

ML operates through two divisions, both focused on the development of high value
pharmaceutical products - Innovata Biomed, the Group's respiratory division, and
ML Pharmaceuticals, a pharmaceutical product development business.

Innovata Biomed (IB) is a leading independent provider of inhaled drug delivery
technologies to the global pharmaceutical industry, formulating dry powders and
developing proprietary inhaler systems through to full industrialisation. IB's
proven delivery technologies are available for proof-of-principle testing and as
fast-to-market drug delivery solutions. It has a number of respiratory products
both in development and marketed by pharmaceutical company licensees including
Celltech, Otsuka and Pliva.

ML's pharmaceutical product development division, ML Pharmaceuticals, contains
both marketed products and new therapeutics in clinical development. Marketed
products include Extraneal for the treatment of renal failure, which has been
licensed to Baxter, and Adept for the reduction of adhesions in abdominal
surgery, which is marketed by Shire Pharmaceuticals in Europe. New therapeutic
products in development include Alpharen, a phosphate binder to assist the
management of kidney failure, treatments for prostate and skin cancer and a pain
management compound.


This information is provided by RNS
The company news service from the London Stock Exchange E

Good news today.
Major restructuring within the company. Streamlining all the offices around the uk into one site. It will cut 65 jobs. Saving millions a year.

SP up 5% today

Nice start to the day up 5% again

SP Starting to move now on the back of a deal. New head guy who is not hanging around in sorting this company out. This is going to fly IMHO. LOL

Lets hope so Troys.
News flow is increasing and the
new board seems to have hit the ground running,
if they keep up the momentum it can only be good
for the future and restore confidence.
Lets hope the worst is now over and the board remains
bullish for it's maiden profit next year.
Regards
HUSTLER

Hustler nicely on the move again. 5% this morning

up 6.58% now. Here we go !!!

Good rise today Troys
finished up 8% with healthy volume
of which 2/3 were buys.
Hope for more tomorrow and next week.
regards
HUSTLER

Lots more to come I think HUSTLER. LOL

Why ?

Its a pile of sh*te thats running out of cash .... AGAIN.

Dil I would of agreed with you for the last 5 years or longer. I am in for the recovery. They have restructured the whole company and we should see the rewards IMHO in the very near future. LOL

Before or after the next cash call ?

I take it you do not like this share now dil?

Hi Dill.
Choked but agree i am afraid cash call
seems on the cards see previous posts,
but sorry to say in to deep to dump
the crap, been a no brainer for years.
Looking at it fresh safe to say you would'nt
bet on it now on fundermentals.
But praying the tide has now turned with new
board - and hay if it does turn round held it
for so long, if there is a profit to be made pay
no tax now that would be a bonus doubt you agree
with me but i have to let it roll, stranger things have happened
still (fcuk) at present but ever hopefull.
regards
HUSTLER

Haven't for years Troys.

Good luck Hustler , you may get a spike on good news or something that may offer you an exit point but I wouldn't hold my breathe.

Some good news today. up 5%

Found a fiver in the tea tin did they ?

Hi dill
well there we have it latest spoof
now buying a profit making company quadrant
for 47 million in cash call for 26 mill
take it the smoke screen allows for a few million for wip
to stop them going bust this year
they must think we are a bunch of wank...
fear going to lose a bundle on this crap
suspect the tea lady nicked the teapot with the duke in it
as it was all that was worth nicking.

regards HUSTLER

Well i'm in profit. Down side from here on looks very slim.Upside looks very good to me.This is a new company now. LOL

ML Laboratories to buy Quadrant in 47m deal
By Michael Jivkov
17 June 2005


ML Laboratories confirmed yesterday it will acquire Quadrant Technologies, which develops and makes products for inhalers, for 47m.

The deal will double the size of the biotech and turn it into a profitable company. Quadrant was spun out of the Irish pharmaceuticals company Elan two years ago via a management buyout and registered a pre-tax profit of 1.3m last year.

According to City analysts, the combined company will generate net income of 8.5m before goodwill and amortisation in its first full year to September 2006. The tie-up will see ML focus on developing products for respiratory diseases. Quadrant, which makes powder drugs for inhalers, fits with ML's Innovata Biomed division which produces inhalers.

The biotech group also announced yesterday that it will buy out minority shareholders at Innovata Biomed, who hold 18.75 per cent of the company. The 1.85m transaction gives it full control of the unit. In an attempt to put its loss-making past behind it, ML plans to change its name to Innovata. It will relocate to Nottingham, where Quadrant is based.

ML shareholders hope that the acquisition will herald a turnaround at the company. Over the past decade the group has raised more than 120m from investors and paid nothing out. At the peak of its powers in 2000, ML was worth more than 1bn and its shares traded at more than 180p. They closed 1p higher at 21.75p yesterday.

Of the total 47m which ML plans to spend on buying Quadrant, 19.5m will be paid in cash. The company's broker, Code Securities, will raise this sum via a placing of 137 million new ML shares at 19p.